Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences during March:

• Barclays Global Healthcare Conference. Zymeworks will participate in one-on-one meetings and will present on March 16th at 8:00 a.m. ET in Miami, FL.
• Citi’s 2022 Winter Biotech Virtual Bus Tour. Zymeworks will participate virtually in a fireside chat on March 23rd at 2:45 p.m. ET.

The fireside chat and presentation will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005388/en/

Investor Inquiries:
Jack Spinks
(604) 678-1388
[email protected]

Media Inquiries:
Diana Papove
(604) 678-1388
[email protected]

Source: Zymeworks Inc.

You May Also Be Interested In

• FairJourney Bio Delivers Antibody Engineering for Novel Tumor-Conditional IL-12 Therapeutic Approach That Unlocks the Potential of Localized Cytokine Activation
• Lucid Announces Munsterhuis Autobedrijven as First Retail Partner in the Netherlands
• Grande Portage Resources Receives State of Alaska Regulatory Clearance for Road Easement